UroGen Pharma Ltd

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
UroGen Pharma Ltd
TickerURGN
CIK #0001668243
CUSIPM96088105
SectorLife Sciences - Pharmaceutical Preparations
Address9 Ha'Ta'Asiya St, Ra'Anana, 4365007
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
UroGen Pharma Ltd 2023-08-14 120.0 M Exemption: 506(b) · Duration: One year or less · Commission: $3,240,000 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001668243] 10-K
[0001668243] 10-Q
[0001668243] 3
[0001668243] 4
[0001668243] 6-K
[0001668243] 8-K
[0001668243] D
[0001668243] SC 13D
[0001668243] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Toronto Dominion Bank UroGen Pharma Ltd [2026-05-15] 0.0
BlackRock Inc UroGen Pharma Ltd [2026-04-27] 0.0
Toronto Dominion Bank UroGen Pharma Ltd [2025-11-14] 0.0
Paradigm Biocapital Advisors LP UroGen Pharma Ltd [2025-08-12] 0.0
Morgan Stanley UroGen Pharma Ltd [2025-08-06] 0.0
Soleus Capital Master Fund LP UroGen Pharma Ltd [2025-06-16] 0.0
Cowen Financial Products LLC UroGen Pharma Ltd [2025-06-13] 0.0
Adage Capital Management LP UroGen Pharma Ltd [2024-11-12] 8.87
BlackRock Inc UroGen Pharma Ltd [2024-11-08] 5.9
Morgan Stanley UroGen Pharma Ltd [2024-11-06] 5.2
BlackRock Inc UroGen Pharma Ltd [2024-10-24] 5.9
Point72 Asset Management LP UroGen Pharma Ltd [2024-06-24] 6.2
Cowen and Company LLC UroGen Pharma Ltd [2024-06-24] 1.21
RTW Investments LP UroGen Pharma Ltd [2024-02-14] 5.6
BlackRock Inc UroGen Pharma Ltd [2024-02-02] 5.6
RA Capital Management LP UroGen Pharma Ltd [2023-12-29] 9.99
Great Point Partners LLC UroGen Pharma Ltd [2023-09-15] 8.51
Monograph Capital Holdings Advisors LLC UroGen Pharma Ltd [2023-08-04] 5.1
Stonepine Capital Management LLC UroGen Pharma Ltd [2022-12-01] 5.2
BlackRock Inc UroGen Pharma Ltd [2022-07-08] 1.5
Credit Suisse AG/ UroGen Pharma Ltd [2021-02-12] 507.0
BlackRock Inc UroGen Pharma Ltd [2020-02-07] 6.5
Wildcat Capital Management LLC UroGen Pharma Ltd [2019-10-04] 2.55
Wellington Management Group LLP UroGen Pharma Ltd [2019-02-12] 6.04
Arkin Moshe UroGen Pharma Ltd [2018-05-24] 9.37
Pontifax Management III GP 2011 Ltd UroGen Pharma Ltd [2018-02-15] 10.6
Consonance Capital Management LP UroGen Pharma Ltd [2018-02-14] 6.38
FMR LLC UroGen Pharma Ltd [2018-02-13] 0.0
Menora Mivtachim Holdings Ltd UroGen Pharma Ltd [2017-11-08] 5.38
ProQuest Investments IV LP UroGen Pharma Ltd [2017-07-20] 11.5
Arkin Moshe UroGen Pharma Ltd [2017-05-30] 13.32
Form 3/4/5 Filer 2011 - 2026
UroGen Pharma Ltd
Wildman Daniel George
Schoenberg Mark
Robinson James A Jr
Holden Stuart
Butitta Cynthia M
Wen Leana
Belldegrun Arie
Barrett Elizabeth A
Smith Jason Drew
Degnan Chris
Kim Dong
Cohen Fred E
Nussbaum Ran
Henderson Molly
Falberg Kathryn E
Tomasello Shawn
Pfreundschuh Peter P
Mullennix Stephen
Bentsur Ron
ProQuest Investments IV LP
ProQuest Associates IV LLC
Moorin Jay
Schreiber Alain
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Smith Jason Drew
Ordinary Shares
2026-02-03 Sell 1,608 $19.69 31,662
Schoenberg Mark
Ordinary Shares
2026-02-03 Sell 3,686 $19.69 72,577
Schoenberg Mark
Ordinary Shares
2026-02-03 Sell 1,843 $19.69 36,289
Smith Jason Drew
Ordinary Shares
2026-02-03 Sell 2,654 $19.69 52,257
Schoenberg Mark
Ordinary Shares
2026-02-03 Sell 1,844 $19.69 36,308
Smith Jason Drew
Ordinary Shares
2026-02-03 Sell 3,217 $19.69 63,343
Schoenberg Mark
Restricted Stock Units · derivative
2026-01-31 Option exercise 3,334 $0.00
Smith Jason Drew
Ordinary Shares
2026-01-31 Option exercise 5,500
Schoenberg Mark
Restricted Stock Units · derivative
2026-01-31 Grant 20,000 $0.00
Barrett Elizabeth A
Restricted Stock Units · derivative
2026-01-31 Grant 153,195 $0.00
Smith Jason Drew
Restricted Stock Units · derivative
2026-01-31 Option exercise 6,667 $0.00
Degnan Chris
Restricted Stock Units · derivative
2026-01-31 Grant 32,609 $0.00
Schoenberg Mark
Restricted Stock Units · derivative
2026-01-31 Option exercise 3,333 $0.00
Smith Jason Drew
Ordinary Shares
2026-01-31 Option exercise 3,333
Schoenberg Mark
Ordinary Shares
2026-01-31 Option exercise 3,333
Schoenberg Mark
Ordinary Shares
2026-01-31 Option exercise 6,666
Smith Jason Drew
Ordinary Shares
2026-01-31 Option exercise 6,667
Schoenberg Mark
Ordinary Shares
2026-01-31 Option exercise 3,334
Smith Jason Drew
Restricted Stock Units · derivative
2026-01-31 Option exercise 3,333 $0.00
Smith Jason Drew
Restricted Stock Units · derivative
2026-01-31 Grant 32,609 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 174 45,055,623
2025-12-31 170 42,294,814
2025-09-30 163 43,995,785
2025-06-30 153 40,209,705
2025-03-31 141 40,546,991
2024-12-31 139 35,118,373
2024-09-30 129 34,068,569
2024-06-30 117 37,327,674
2024-03-31 113 26,611,534
2023-12-31 107 20,325,989
2023-09-30 103 16,195,244
2023-06-30 87 11,516,035
Form 13F Holdings
Firm Period DFND Voting Shares
Hennion & Walsh Asset Management Inc [2026-06-30] SOLE 276,696 276,696
Wealth Enhancement Advisory Services LLC [2026-06-30] SOLE 199 7,642
Brookstone Capital Management [2026-06-30] SOLE 0 6,000
Activest Wealth Management [2026-06-30] SOLE 0 1,001
Gamma Investing LLC [2026-06-30] DFND 441 441
IFP Advisors LLC [2026-06-30] SOLE 31 31
Farther Finance Advisors LLC [2026-06-30] SOLE 0 24
True Wealth Design LLC [2026-06-30] SOLE 0 16
Hughes Financial Services LLC [2026-06-30] SOLE 3 3
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com